Jump to content

This woman is a scumbag, and rightly should burn in hell.


Recommended Posts

  • Replies 54
  • Created
  • Last Reply

Top Posters In This Topic

And in the outrage, nobody is going to ask the questions on why aren't there competing alternatives to a 30-year old medicine & technology, and why US consumers continue to subsidize the rest of the world's medical drug buyers.

Link to comment
Share on other sites

Here's my favorite part:

 

The Clinton campaign quickly called those rebate "insufficient," and renewed called for a price slash on EpiPens.

 

Next week we'll get the report that the Clinton campaign is 100% behind Mylan after it was announced the company made a $500,000 donation to the Clinton Foundation.

Link to comment
Share on other sites

Here's my favorite part:

 

 

Next week we'll get the report that the Clinton campaign is 100% behind Mylan after it was announced the company made a $500,000 donation to the Clinton Foundation.

 

I was surprised to see ABC running this:

 

http://abcnews.go.com/Health/senator-joe-manchin-questions-epipen-pricing-company-daughter/story?id=41644437

Link to comment
Share on other sites

And in the outrage, nobody is going to ask the questions on why aren't there competing alternatives to a 30-year old medicine & technology, and why US consumers continue to subsidize the rest of the world's medical drug buyers.

First thing I thought of WRT this story. The delivery mechanism is about $0.20 in cost. Epinephrine isn't patent protected. Some enterprising generic company could come in and take a huge chunk of that market pretty easily IMHO. That's the only thing that will make the Whipley Snidelash roll back their pricing. :ph34r:

Link to comment
Share on other sites

First thing I thought of WRT this story. The delivery mechanism is about $0.20 in cost. Epinephrine isn't patent protected. Some enterprising generic company could come in and take a huge chunk of that market pretty easily IMHO. That's the only thing that will make the Whipley Snidelash roll back their pricing. :ph34r:

 

WSJ is blaming the FDA for stonewalling competitive products, for whom trials have been delayed or blocked.

Link to comment
Share on other sites

 

WSJ is blaming the FDA for stonewalling competitive products, for whom trials have been delayed or blocked.

 

Is the WSJ correct?

 

Even if they are correct, does it satisfy the manufacturer's flimsy complaints that underpin their decision to raise prices on an exponential curve? Or is it that the cost of epinephrine and plastic injector production's increased 500%?

So companies should sell products at a price that everyone can afford regardless of how much profit they make off of the product?

 

Question for you:

 

Do you figure the cost of production of epinephrine and plastic injectors has increased 500%? Or is it just a means to finance the CEO's $16 million pay increase? http://www.nbcnews.com/business/consumer/mylan-execs-gave-themselves-raises-they-hiked-epipen-prices-n636591

 

How many yachts does that woman need, anyway?

And in the outrage, nobody is going to ask the questions on why aren't there competing alternatives to a 30-year old medicine & technology, and why US consumers continue to subsidize the rest of the world's medical drug buyers.

 

Answer to the second part of that question's a no-brainer. The rest of the world sets price limits on drugs. The US doesn't. So, the companies gouge the public, and use the profits to ensure that the legislative environment stays exactly as it is.

 

As to the first part, it seems like Mylan's put on a full-court lobbying play to keep their little niche all to themselves, at the expense of consumers.

 

Aaaaaand in more Mylan news, our ne'er-do-well CEO with a fake MBA is also encouraging the firm she runs to dodge taxes (see the bottom of this article from the bastion of socialist thought that is "Forbes"):

 

http://www.forbes.com/sites/emilywillingham/2016/08/23/ceo-of-mylan-pharmaceuticals-sees-671-salary-increase-in-8-years/#77a5b5c44b23

Edited by joesixpack
Link to comment
Share on other sites

Simmah down Joe. She's the daughter of a Senator. A Democrat Senator. Learn to chill.

I know somebody that works for them (Dr. In chemistry) up in Vermont. They were all in a snit a few years ago when Mylan wanted to move operations to W.Virginia. I always wondered why. I guess the employees voted no back then.

 

Yes... All holier than thou Vermont!

oh God, think of the children....

Just avoid tree nuts. Anyway, back in the day, nobody had allergies, let alone 2 600 buck Epipens, w/a year's shelf life, on standby.

Link to comment
Share on other sites

And in the outrage, nobody is going to ask the questions on why aren't there competing alternatives to a 30-year old medicine & technology, and why US consumers continue to subsidize the rest of the world's medical drug buyers.

 

 

Yes, this is mostly true, (even though arguing pharmaceutical policy of foreign countries is akin to arguing about the effects of globalization, it's useless) still doesn't take away the fact that it was a complete douchebag greedy sort of move. And that company is now paying the price

Link to comment
Share on other sites

Here is my favorite part:

 

But she also acknowledged that high retail prices of EpiPens in the United States effectively subsidize the cost of the devices when they are sold in Europe, at just $100 or $150. Many of the countries there have government-run health-care systems that limit drug prices charged by manufacturers, unlike the U.S.

 

"We do subsidize the rest of the world... and as a country we've made a conscious decision to do that," Bresch said. "And I think the world's a better place for it."

 

She's right. Since we don't have "socialized medicine", we get the privilege of paying exhorbanent prices for drugs, care, and insurance. The free global trade seems to have bitten us on the behind. Edited by reddogblitz
Link to comment
Share on other sites

I'd like to know why the EpiPen has increased 500% in seven years before I go blaming the CEO's desire for a new yacht, personally.

 

Mostly because I don't assume the distribution chain is from the CEO straight to the consumer.

Link to comment
Share on other sites

I'd like to know why the EpiPen has increased 500% in seven years before I go blaming the CEO's desire for a new yacht, personally.

 

Mostly because I don't assume the distribution chain is from the CEO straight to the consumer.

Don't be silly. If you can't make a knee jerk reaction based on emotion from the clear facts that initial article contained, then you're just being ridiculous.

Link to comment
Share on other sites

×
×
  • Create New...